Biktarvy – Talk Bio

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

4 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook

6 months ago talkbio0Tagged Advice, annual, Biktarvy, earnings, Gilead Sciences, HIV, HIV Prevention, Lenacapavir, Veklury

Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention

GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial

9 months ago talkbio0Tagged Biktarvy, DOBLE, Dovato, Gilead, HIV, PASO, SmithKline Beecham, Spanish, Spanish Language, ViiV Healthcare

GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare